Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04898101 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

A Phase 1 study of Healthy Volunteers, sponsored by Acerta Pharma.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT04898101 is a Phase 1 study of Healthy Volunteers that has completed, run by Acerta Pharma. The registered enrollment target is 14 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04898101, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Acerta Pharma.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This study is to determine the absolute bioavailability of oral acalabrutinib and intravenous (IV) PK of \[14C\]ACP-196.

Conditions Studied

Healthy Volunteers

Interventions

  • DRUG Acalabrutinib
  • DRUG Microtracer [14C]ACP-196

Study Locations (1)

Wisconsin

  • Covance Clinical Research Unit, Inc. - Madison

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2016-03-03
Est. Completion 2016-04-13
Phase Phase 1

Sponsor

Acerta Pharma

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04898101

The ClinicalTrials.gov registry entry for NCT04898101 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower). The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Acalabrutinib is the first listed.

NCT04898101 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT04898101 about?

NCT04898101 is a clinical study titled "A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants". This study is to determine the absolute bioavailability of oral acalabrutinib and intravenous (IV) PK of \[14C\]ACP-196.

What is the current status of trial NCT04898101?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-03-03. Estimated completion is 2016-04-13.

What conditions does trial NCT04898101 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT04898101?

The interventions under investigation include: Acalabrutinib (DRUG), Microtracer [14C]ACP-196 (DRUG).

Who is sponsoring clinical trial NCT04898101?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04898101 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy Volunteers

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.